A possible survival advantage in patients with metastatic uveal melanoma who respond to treatment with pembrolizumab is suggested in a study of the anti-PD-1 monoclonal antibody as immunotherapy for advanced disease.
Researchers enrolled 17 patients with metastatic uveal melanoma in a prospective observational cohort single-arm study to investigate efficacy and safety of pembrolizumab as a first line-therapy. Endpoints were progression-free survival, complete or partial response or disease stabilization, clinical benefit, overall survival and tolerability.
A median of eight cycles of
Uncategorized